![Erasca, Inc. logo](/logos/ERAS.webp)
Erasca, Inc.
NASDAQ:ERAS
Overview | Financials
Company Name | Erasca, Inc. |
Symbol | ERAS |
Currency | USD |
Price | 2.86 |
Market Cap | 807,961,440 |
Dividend Yield | 0% |
52-week-range | 1.51 - 3.45 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Jonathan E. Lim M.D. |
Website | https://www.erasca.com |
An error occurred while fetching data.
About Erasca, Inc.
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD